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Currently, limited data of the outcome of inflammatory bowel disease (IBD) in patients after
solid organ transplantation (SOT) are available. We aimed to analyze effects of SOT on the
IBD course in a large IBD patient cohort.
Methods
Clinical data from 1537 IBD patients were analyzed for patients who underwent SOT (n =
31) between July 2002 and May 2014. Sub-analyses included SOT outcome parameters,
IBD activity before and after SOT, and efficacy of IBD treatment.
Results
4.74% of patients with ulcerative colitis (UC) and 0.84% of patients with Crohn’s disease
(CD) underwent SOT (p = 2.69 x 10−6, UC vs. CD). 77.4% of patients with SOT underwent
liver transplantation (LTx) with tacrolimus-based immunosuppressive therapy after SOT. All
LTx were due to primary sclerosing cholangitis (PSC) or PSC overlap syndromes. Six
patients (19.4%) required renal transplantation and one patient (3.2%) heart transplanta-
tion. A survival rate of 83.9% after a median follow-up period of 103 months was observed.
Before SOT, 65.0% of patients were in clinical remission and 5 patients received
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immunosuppressive therapy (16.1%). After SOT, 61.0% of patients were in remission (p =
1.00 vs. before SOT) and 29.0% required IBD-specific immunosuppressive or anti-TNF
therapy (p = 0.54 vs. before SOT). 42.9% of patients with worsening of IBD after SOT were
at higher risk of needing steroid therapy for increased IBD activity (p = 0.03; relative risk
(RR): 10.29; 95% CI 1.26–84.06). Four patients (13.0%) needed anti-TNF therapy after
SOT (response rate 75%).
Conclusions
SOT was more common in UC patients due to the higher prevalence of PSC-related liver
cirrhosis in UC. Despite mainly tacrolimus-based immunosuppressive regimens, outcome
of SOT and IBD was excellent in this cohort. In this SOT cohort, concomitant immunosup-
pressive therapy due to IBD was well tolerated.
Introduction
The clinical course of inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and
Crohn’s disease (CD) is typically characterized by alternating episodes of flares and remission.
In up to one third of IBD patients, extraintestinal manifestations such as primary sclerosing
cholangitis (PSC) or renal dysfunction (e.g., due to amyloidosis) are found [1–3].
PSC is a chronic cholestatic liver disease with chronic inflammation and fibrosis of hepatic
bile ducts, resulting in liver cirrhosis and progressive impairment of liver function and conse-
cutive liver failure in a subgroup of PSC patients [3, 4]. Liver transplantation is currently the
only curative therapy for PSC as medical treatments are limited and non-curative in PSC [5].
PSC is more frequent in UC patients than in CD patients with prevalence rates of PSC ranging
from 0.76% to 5.4% in UC patients and from 1.2% to 3.4% in CD patients [1, 6–8]. Most IBD
patients with PSC display a characteristic disease course compared to IBD patients without
cholestatic liver diseases [4, 8–17]. Furthermore, the frequency of pancolitis is higher in
UC-PSC patients with more right-sided colitis; and more of these patients have rectal sparing
and backwash ileitis, although the course of UC is often mild [4, 9–12, 14, 15, 18]. In contrast,
the risk of malignancies including colorectal cancer (CRC) and cholangiocarcinoma is signifi-
cantly increased in UC patients with concomitant PSC, independently from the underlying
risk of CRC in UC alone [13, 16, 17, 19]. In addition, the risk of pouchitis was reported to be
high after proctocolectomy with ileal pouch-anal anastomosis (IPAA) [9].
Given the high prevalence of PSC among IBD patients, PSC is the most frequent cause for
liver transplantation (LTx) in IBD patients. Another less frequent cause for solid organ trans-
plantation (SOT) in IBD patients is renal insufficiency, e.g., due to amyloidosis [2, 20]. In IBD
patients undergoing SOT, the disease course is highly variable after SOT and data on the subse-
quent IBD course after SOT are conflicting [2, 3, 9–18, 20–31]. A recently published meta-anal-
ysis included a total of 609 IBD patients of 14 clinical studies and investigated the natural
history of IBD after LTx in patients with PSC/UC. Among these IBD patients, one third (31%)
showed improvement of IBD activity after LTx, 39% of patients displayed no significant change
of IBD activity, whereas in 30% of patients the IBD activity worsened after LTx with need for
treatment intensification after LTx [5]. Similarly, after renal transplantation, approximately
30% of patients develop IBD flares and one fifth of patients have to undergo colectomy after
IBD and Solid Organ Transplantation
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renal transplantation [32–35]. Therefore, for approximately one third of IBD patients treat-
ment has to be adapted due to the increasing activity of IBD after SOT.
Anti-tumour necrosis factor alpha (TNF-α) therapy has proven to be an effective therapeu-
tic option in patients with refractory IBD in numerous clinical trials. Therefore, anti-TNF-α
therapy represents a treatment option in IBD patients who underwent SOT. However, clinical
experience of anti-TNF-α therapy in IBD patients after SOT is very limited. To date, a total of
21 IBD patients including patients with UC, CD, indeterminate colitis and pouchitis, have
been treated with infliximab or adalimumab after LTx [36–40]. Some case reports were pub-
lished on anti-TNF-α therapy in IBD patients after renal transplantation but no data exist on
anti-TNF-α therapy in IBD after heart transplantation [41, 42].
Given the rare incidence of SOT in IBD patients, our large IBD patient cohort enabled us to
perform a large single center study (n = 31 SOT cases) on the IBD disease course and anti-
TNF-treatment efficacy before and after SOT in a well-characterized IBD cohort.
One aim was to investigate the outcome of SOT in IBD patients and to evaluate the course
of IBD before and after SOT. In addition, we aimed to analyze the treatment outcome of anti-
TNF therapy among these patients. These data were finally compared to other available clinical
trials and analyses of SOT in IBD patients.
Materials and Methods
Ethical Statement
All individuals gave their written, informed consent prior to study inclusion. The study was
approved by the local Ethics committee (Ludwig-Maximilians-University Munich) and
adhered to the ethical principles for medical research involving human subjects of the Helsinki
Declaration.
Study population
All IBD patients were recruited from the IBD outpatient department of the University Hospital
Munich-Grosshadern and from our Center for Solid Organ Transplantation (Ludwig-Maximi-
lians-University Munich, Germany). Databases of all IBD patients who were followed at the
IBD outpatient department and of all patients who underwent SOT at the University Hospital
Munich-Grosshadern or were followed after SOT at our Center for Solid Organ Transplanta-
tion, respectively, were merged to identify IBD patients who underwent SOT. Two senior gas-
troenterologists viewed relevant data of the 31 IBD patients who underwent SOT between July
2002 and May 2014. Clinical data was collected prospectively. However, data analysis was per-
formed retrospectively. Two senior gastroenterologists analyzed the data which were recorded
by patients’ chart analysis and a detailed questionnaire based on an interview at time of enrol-
ment. All patients were regularly seen at the IBD outpatient department and at the Center for
Solid Organ Transplantation at the University Hospital Munich—Grosshadern. The diagnosis
of UC and CD was based on the Montréal classification including endoscopic, radiological, and
histopathological parameters [43]. IBD activity was evaluated clinically before and after SOT
and was based on endoscopic findings before and after SOT. Endoscopic assessment for UC
was based on the Mayo endoscopic subscore with (0) for inactive disease, (1) for mild disease
with erythema, decreased vascular pattern, mild friability, (2) for moderate disease with
marked erythema, absent vascular pattern, friability, erosions and (3) for severe disease with
spontaneous bleeding and ulcerations. For CD, endoscopic activity was defined as “remissio-
n”in case of the absence of erosions, ulcers and stenosis and fistulas, respectively and “mild”in
case of signs of inflammation with erosions and absence of ulcers, stenosis and fistulas, respec-
tively, and “severe”in case of ulcerations, stenosis or fistulas. For clinical assessment of CD, the
IBD and Solid Organ Transplantation
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Crohn's Disease Activity Index (CDAI) was used; a score of< 150 points was defined as clini-
cal remission. For UC, the Clinical Activity Index (CAI, Lichtiger score) was used; a CAI of 4
points was defined as clinical remission. For endoscopic activity, the last endoscopy before
SOT and the first endoscopy after SOT were analyzed. Steroid treatment after SOT for IBD was
defined as daily steroid treatment> 10 mg prednisolone due to high IBD activity.
Statistical analysis
Data were described with proportions for categorical variables and median with range for con-
tinuous variables. Crude associations between categorical variables were assessed with the Chi-
square test or the Fisher’s exact test, where appropriate. Quantitative variables were compared
between subgroups using Student’s t-test. All tests were two-tailed and p-values< 0.05 were
considered as significant.
Results
Solid organ transplantation in IBD patients
Out of a total IBD cohort of 1073 CD patients and 464 UC patients analyzed in this study, 31
patients (2.0% of all IBD patients) underwent SOT during the study period (between July 2002
and May 2014). Among the 31 IBD patients were 22 UC patients (71.0%) and 9 CD patients
(29.0%). Therefore, 0.84% of all 1073 CD patients and 22 of all 464 UC patients (4.74%) under-
went SOT, confirming the increased incidence of SOT among UC patients compared to CD
patients (p = 2.69 x 10−6, UC vs. CD). Twenty-four IBD patients underwent LTx (77.4%), six
IBD patients underwent kidney transplantation (19.4%) and one patient underwent heart
transplantation (3.2%; Table 1, Fig 1).
Outcome of liver transplantation in IBD patients
Twenty-four IBD patients including 21 UC patients and 3 CD patients underwent LTx for PSC
or PSC/AIH overlap syndrome; one UC patient had concomitant PSC and hemochromatosis
(Fig 1, Table 1). The median age at first diagnosis of liver disease was 27.2 years (range 12.5–
56.0 years), compared to a median age of 21.2 years at first IBD diagnosis (range 9.1–50.0
years). The median age at first LTx was 41.2 years (range 27.1–66.0 years). Therefore, the
median interval from first diagnosis of liver disease to LTx was 156.8 months (range 10.1–
418.0 months).
All patients with LTx received immunosuppressive therapy with tacrolimus after transplan-
tation, five patients received tacrolimus in combination with mycophenolate mofetil (MMF)
(20.8% of all LTx patients), 17 patients received concomitant steroid treatment (70.8%) and
one UC patient received consecutively cyclosporine A and then tacrolimus (4.2%, Table 1).
Three of the 24 IBD patients (12.5%) needed re-transplantation because of acute ischemic
organ failure after first LTx; one of them (4.2%) required even a total of four LTx due to recur-
rent acute ischemic organ failures after transplantation (Table 1). One UC patient (4.2%)
needed a second LTx one month after first SOT because of organ failure after recurrent cholan-
gitis and intra-hepatic bleeding complications. Another UC/PSC patient (4.2%) needed re-
transplantation three years after first LTx because of chronic vascular complications resulting
in a chronic ischemic organ failure (Table 1).
Outcome of renal transplantation in IBD patients
Six IBD patients out of 1537 IBD patients analyzed (0.4%), including five CD patients (0.47%
of all CD patients) and one UC patient (0.22% of all UC patients) underwent renal
IBD and Solid Organ Transplantation
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transplantation for terminal renal failure (Fig 1, Table 1). Two out of these six patients (33%)
were diagnosed with AA amyloidosis resulting in chronic renal failure. Another UC patient
(16.7%) was diagnosed with IgA nephropathy. One CD patient (16.7%) was diagnosed with
oxalate nephropathy and consecutive chronic renal failure needing hemodialysis followed by
renal transplantation. Another CD patient (16.6%) developed an acute hemolytic uremic syn-
drome with acute renal failure and underwent renal transplantation (Table 1). In one CD
patient with chronic renal failure, the cause for renal failure could not been diagnosed
(Table 1). Median age at first diagnosis of renal disease was 35.8 years (range 14.4–56.9 years)
compared to a median age at first diagnosis of IBD of 27.1 years (range 8.4–43.0 years). The
median age at first renal transplantation was 43.6 years (range 28.5–66.3 years). Therefore, the
median interval from first diagnosis of kidney disease to renal transplantation was 101.0
months (range 0.0–177.1 months). Three of the six IBD patients (50.0%) received cyclosporine
A (CyA) after renal transplantation (one patient with CyA mono therapy, one CyA with ste-
roids, and one CyA with MMF treatment, Table 1). Two IBD patients (33.3%) received tacroli-
mus after kidney transplantation (one patient with combination therapy with steroids and one
patient with concomitant MMF treatment, Table 1). Another IBD patient received MMF and
steroid treatment after renal transplantation. In summary, five of the six IBD patients (83.3%)
had concomitant steroid treatment after transplantation.
Fig 1. Indication for solid organ transplantation (SOT). A total of 31 patients (22 UC patients and 9 CD patients underwent SOT between July 2002 and
May 2014). Twenty-four IBD patients (21 UC patients and 3 CD patients) underwent orthotopic LTx (77.4%) and 6 IBD patients (1 UC patient and 5 CD
patients) underwent renal transplantation (19.4% off all SOT) and one CD patient underwent heart transplantation (3.2% of all SOT) (PSC, primary sclerosing
cholangitis; AIH, autoimmune hepatitis; HUS, acute hemolytic uremic syndrome; CRF, chronic renal failure; LTx, liver transplantation; UC, ulcerative colitis;
CD, Crohn’s disease).
doi:10.1371/journal.pone.0135807.g001
IBD and Solid Organ Transplantation
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Outcome of solid organ transplantation in the IBD patient with heart
transplantation
One CD patient out of 1537 IBD patients analyzed (0.07%) underwent heart transplantation
because of ischemic dilatative cardiomyopathy with consecutive congestive heart failure at age
of 29 years (Fig 1, Table 1). This patient was diagnosed with CD at age of 22 years and received
tacrolimus, MMF and steroid treatment after heart transplantation. The time from diagnosis of
heart failure to heart transplantation was 15 months.
IBD activity and medical treatment before and after solid organ
transplantation
Clinical characteristics of UC and CD based on the Montreal classification, disease activity
before and after SOT, as well as history of IBD-related surgery and IBD-related medical treat-
ment before and after SOT are given for the 22 UC patients and 9 CD patients in Table 1. All
31 IBD patients underwent endoscopy within a median of 16.5 months before SOT; they
underwent also endoscopy within a median of 24.4 months after SOT.
Overall, 20 of the 31 IBD patients were clinically and endoscopically in remission before
SOT (64.5%). Six IBD patients had mild disease activity before SOT (19.4%) and five IBD
patients had severe IBD activity before SOT (16.1%, Table 1, Fig 2A). After SOT, no activity of
IBD was endoscopically seen in 19 of the 31 IBD patients (61.3%), while nine IBD patients had
mild disease activity after SOT (29.0%) and three patients (9.7%) had severe disease activity
(Table 1, Fig 2B).
History of medical treatment before and after SOT is given in Table 1 and Fig 3. Sixteen UC
patients (out of 22 UC patients with SOT; 72.8%) received 5-amino-salicylic acid (5-ASA)
treatment pre-SOT, eight patients received steroids (36.4%) and one patient with severe panco-
litis received azathioprine (4.5%), while five UC patients had no maintenance treatment before
SOT (22.7%, Table 1, Fig 3). After SOT, nine of the 22 UC patients received 5-ASA treatment
(40.9%), three patients needed steroid treatment (13.6%) and two UC patients had immuno-
suppressive therapy with azathioprine after SOT (9.1%, Table 1, Fig 3). Two UC patients
(9.1%) were treated with infliximab after SOT and another UC patient was treated with adali-
mumab 2.5 years after SOT (Table 1, Fig 3).
Four of the nine CD patients had no maintenance treatment before SOT (44.4%, Table 1,
Fig 3), two CD patients had immunosuppressive therapy with azathioprine (22.2%) and two
other CD patients received 6-mercaptopurine (22.2%). Three CD patients had steroid treat-
ment with two of them receiving concomitant immunosuppressive treatment with azathio-
prine and 6-mercaptopurine, respectively, and 5-ASA in one of these patients (33.3%, Table 1,
Fig 3). After SOT, one CD patient was treated with infliximab (Table 1 and Fig 3). One patient
received steroid treatment after SOT because of increased CD activity (11.1%), 3 patients had
immunosuppressive therapy with azathioprine after SOT (33.3%) and five patients (55.6%)
had no IBD-specific treatment after SOT (Table 1, Fig 3).
IBD activity changes after solid organ transplantation
A change of disease activity was seen in twelve of the 31 IBD patients after single organ trans-
plantation (39%), while in 19 patients (61%) no significant influence of SOT on IBD activity
was observed. Worsening of disease activity after SOT was seen in 7 patients (23%), while IBD
activity decreased in five patients after SOT (16%; Table 1, Fig 4).
Univariate analysis revealed that requirement of additional corticosteroid therapy (defined
as prednisolone equivalent of 10 mg or greater for IBD activity and not for therapy of
IBD and Solid Organ Transplantation
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transplant rejection) was a good predictor for worsening IBD activity after SOT (p = 0.03; rela-
tive risk (RR): 10.29; 95% CI 1.26–84.06; Table 2).
Severe complications after solid organ transplantation
Overall, there was a survival rate of 83.9% after a mean follow-up period of 33.3 months (range
0.1–242.4 months) after SOT. During a total follow-up time of 103.0 months (range 7.0–182.0
months) and a median follow-up of 33.3 months (range 0.1–242.4 months) after SOT, a total
Fig 2. Endoscopic disease activity seen (A) before single organ transplantation (SOT) and (B) after SOT.Overall, 20 of the 31 IBD patients were
endoscopically in remission before SOT (64.5%) compared to six IBD patients with mild disease activity before SOT (19.4%) and five IBD patients with
severe IBD activity before SOT (16.1%). After SOT, no activity of IBD was endoscopically seen in 19 of the 31 IBD patients (61.3%) versus nine IBD patients
with mild disease activity after SOT (29.0%) and severe disease activity in three IBD patients (9.7%).
doi:10.1371/journal.pone.0135807.g002
IBD and Solid Organ Transplantation
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of 6 IBD patients who underwent SOT died (16.1%) at a median age of 49.0 years (range 34.6–
57.2 years, Table 1). All patients who died during the follow-up interval were male patients.
Three male UC patients who underwent LTx for PSC (9.7%) died because of acute ischemic
failure of the transplanted liver after a median of 5.8 months (range 3.6–8.9 months). One male
CD-PSC patient (3.2%) died one year after LTx because of septic and bleeding complications at
an age of 35 years. This patient received MMF, steroids and tacrolimus as immunosuppressive
regimen after SOT. Another male UC patient who underwent a total of four LTx because of
recurrent acute ischemic organ failures died six years after the last LTx because of septic compli-
cations and gastro-intestinal bleeding complications at an age of 35 years with concomitant
Fig 3. Medical treatment for IBD before and after single organ transplantation (n = 31).Given are the total number of patients and proportion of patients
for the relevant IBD treatment. (5-ASA, aminosalicylates; AZA, azathioprine; 6-MP, 6-mercaptopurine; IFX, infliximab; ADA, adalimumab). * excludes short-
term steroid treatment for SOT.
doi:10.1371/journal.pone.0135807.g003
Fig 4. Change of IBD activity in our cohort of 31 IBD patients.
doi:10.1371/journal.pone.0135807.g004
IBD and Solid Organ Transplantation
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immunosuppressive therapy with tacrolimus (3.2%, Table 1). Two years after LTx, another male
UC-PSC patient died because of congestive heart failure (3.2%, Table 1). Despite incomplete
data regarding the cytomegalovirus (CMV) infection status before SOT, none of the 31 IBD
patients with SOT developed infectious complications related to CMV or CMV reactivation.
Malignancies in IBD patients before and after SOT
Almost one third of the 31 IBD-SOT patients were diagnosed with malignancies or dysplasia
(n = 9, 29%). Six IBD patients (19.4%) were diagnosed with malignancy or dysplasia before
SOT (6/9 patients, 66.7%: one male UC patient with abdominal cutaneous malignant mesothe-
lioma; one female UC patient with cholangiocellular carcinoma diagnosed in the explanted
liver; one male UC patient with hepatocellular carcinoma diagnosed in the explanted liver; one
male UC patient with severe pancolitis was diagnosed with high-grade dysplasia-associated
lesions (DALM); one male CD patient with cholangiocellular carcinoma diagnosed in the
explanted liver and one UC patient with colorectal cancer before SOT; Table 1).
Three IBD patients (9.7%) were diagnosed with malignancies after SOT (one female UC
patient with adenocarcinoma of the papilla of Vater; one male CD patient with post-transplant
lymphoproliferative disease (PTLD) and male CD patient with papillary renal cell carcinoma
in the transplanted kidney; Table 1).
Discussion
The aim of this study was to analyze the effect of SOT on the IBD course. Only a minority of
2% of all IBD patients (31 out of 1537 IBD patients) needed SOT in our IBD cohort demon-
strating that this is an overall rare event in IBD, especially in CD patients. Importantly, signifi-
cantly more UC patients underwent SOT in our study cohort compared to CD patients due to
the higher prevalence of PSC-related liver cirrhosis in UC (4.74% of all UC patients vs. 0.84%
of all CD patients, p = 2.69 x 10−6). All LTx were performed due to PSC or PSC overlap syn-
dromes. Epidemiologic data from Northern European countries demonstrated a lifetime risk of
5% for developing PSC in IBD patients [6]. Also in Northern European countries, PSC is a
major indication for LTx constituting approximately 17% of all indications for LTx in the gen-
eral population (including IBD patients) [21].
Overall, outcome of SOT in the 31 patients was favourable in our cohort. The survival rate
was 84% (n = 26) during a total follow-up of 103.0 months (range 7.0–182.0 months) and a
median follow-up period of 33.3 months after SOT (Table 1). Five male IBD patients who
underwent SOT died (16%) at a median age of 49.0 years. Most common complications were
ischemic organ failure of the transplanted liver, septic complications as well as uncontrollable
bleeding complications.
Renal failure is a rare complication especially in patients with CD [20]. Age and duration of
IBD have been identified as independent risk factors to develop renal failure [44]. Systemic AA
amyloidosis is associated with IBD and at least 1% of IBD patients will develop amyloidosis
[45]. Two of our CD patients needed renal transplantation for AA amyloidosis and had favour-
able long-term outcomes. An association between IgA nephropathy and IBD seems possible
[46] and there is an between oxalate nephropathy and IBD since the prevalence of calcium-
oxalate urolithiasis is up to five-fold higher in CD than in the general population [47]. Hemo-
lytic-uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia,
impaired renal function and excessive platelet consumption leading to thrombocytopenia espe-
cially related to gastrointestinal tract infections with Shiga toxin-producing Escherichia coli
(STEC) [48]. CD seems to be a likely predisposing factor for HUS because of recurrent gastro-
intestinal tract infections [49].
IBD and Solid Organ Transplantation
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Importantly, the majority of IBD patients in our cohort received a tacrolimus-based anti-
reject treatment regimen after SOT (87.1%). In some studies, this immunosuppressive treat-
ment regimen was associated with an unfavourable outcome in IBD patients who underwent
SOT with an up to four-fold higher risk of post-LTx IBD relapse [5, 50–52]. However, we
could not confirm this unfavourable outcome in IBD patients with tacrolimus-based anti-reject
treatment regimen post-SOT as in 61% of patients disease activity was not influenced by SOT
(and SOT-associated immunosuppressive therapy) and 16% of patients had even improvement
of disease activity after SOT.
Cyclosporine-based anti-reject regimens after SOT were not associated with worsening of
disease activity in patients with IBD [52, 53]. However, only four of our 31 IBD patients
(13.0%, 3 CD patients and one UC patient) had cyclosporine-based immunosuppression after
SOT (Table 1). Disease activity did not change in two of these patients after start of cyclospor-
ine A; two patients had mild activity after SOT while all patients were clinically and endoscopi-
cally in remission before SOT. However, our subgroup of patients with cyclosporine A
treatment after SOT is too small to draw definite conclusions. These observations were con-
firmed by univariate analysis of risk factors, demonstrating no association between tacrolimus
or cyclosporine treatment after SOT with worsening of disease activity.
Steroid treatment for IBD after SOT was associated with active disease in this univariate
analysis (p = 0.028, Table 2). This association may be most likely explained by the fact that
patients with active IBD after SOT will be primarily started with steroid treatment to control
disease activity considering the limited experience with other treatment options for IBD main-
tenance therapy after SOT such as anti-TNF treatment. Therefore, steroid therapy is not neces-
sarily a predictor of disease worsening after SOT but rather an indicator for active IBD
following SOT.
Based on the results of a large Scandinavian meta-analysis with unfavourable outcomes of
IBD under tacrolimus-based anti-reject treatment regimen after liver transplantation, Jørgensen
et al. suggested a shift of immunosuppressive treatment to cyclosporine as potentially beneficial
[5, 21]. However, tacrolimus-based anti-reject therapy seems superior to cyclosporine-based
anti-reject treatment regimen by significantly reducing the risk of acute rejection and steroid-
resistant rejection as well as the risk of graft loss [54]. For every 100 LTx patients treated with
tacrolimus instead of cyclosporine, rejection and graft loss could be avoided in 9 and 5 patients,
respectively [54]. None of the IBD patients in our cohort had severe episodes of acute rejection
after SOT or loss of the transplant due to acute rejection reaction. Therefore, our data cannot
support unfavourable outcomes of the IBD course in tacrolimus-treated patients. Taking the
lower risk of acute rejection and steroid-resistant rejection as well as the lower risk of graft loss
in patients with tacrolimus treatment into account, a switch to cyclosporine in IBD patients
with SOT cannot be recommended considering the results of our study.
Although calcineurin inhibitors (CNIs) are the main anti-reject treatment after LTx, CNI
treatment is associated with unfavourable side effects such as worsening of renal dysfunction,
neurotoxicity, and diabetes in patients following LTx. The use of mammalian target of rapamy-
cin (mTOR) inhibitors after liver transplantation has been associated with favourable benefits
on renal function but with efficacy comparable to CNIs and therefore would be a good alterna-
tive in IBD patients following LTx [55]. However, data on mTOR treatment for IBD are very
limited and currently not established to control disease activity in patients with IBD [55].
Data on the prevalence of colectomy after SOT are conflicting. Whereas a progressive PSC
with a consecutive need for LTx seems to be associated with a decrease of disease activity in
some IBD/PSC patients, other clinical trials report a prevalence of colectomy of up to 35% in
UC patients after LTx [56, 57]. In our cohort, only one patient needed colectomy after SOT
because of refractory pancolitis despite anti-TNF maintenance treatment with infliximab.
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In the literature, a total of 21 patients with anti-TNF treatment after SOT are reported to
date [36–40]. The majority of these patients showed good response rates after start of anti-TNF
treatment. With the exception of one study [37], which demonstrated in several patients infec-
tious complications and a case of post-transplant lymphoproliferative disorder, there was also
an overall good safety outcome (Table 3). Considering the patient number of these studies
combined (n = 21), the clinical experience of anti-TNF-treated IBD patients with SOT is still
very limited. In addition, the overall incidence of SOT in IBD is rare; therefore, very large stud-
ies are needed to draw definitive conclusions on the safety of anti-TNF therapies in SOT
patients.
In our cohort, four patients (13.0%) received anti-TNF treatment after SOT, including one
CD patient after heart transplantation. This patient suffered from an inflammatory intestinal
stenosis before heart transplantation. After start of infliximab, this patient was clinically in
Table 2. Comparison of IBD-SOT patients with unchanged or improved IBD activity (n = 24) and IBD--
SOT patients with worsened IBD activity (n = 7; univariate analysis). Steroid treatment for IBD after SOT
was significantly associated with worsening of disease activity (p = 0.028). However, this association may be
most likely explained by the fact that IBD patients with worsening of IBD activity after SOT will be primarily
treated with steroid treatment rather than steroid treatment being an independent risk factor for worsening of
IBD activity after SOT.
Variable Disease activity
unchangedor improved




OR 95% CI p
value
Male sex 18/24 (75.0%) 5/7 (71.4%) 1.193 0.091/
10.112
1.000
Age < 20 years at
diagnosis of IBD
7/24 (29.2%) 4/7 (57.1%) 0.322 0.037/
2.449
0.210
Smoking at date of
SOT
1/24 (4.2%) 1/7 (14.3) 0.276 0.003/
23.864
0.406
IBD in remission before
SOT
13/20 (65.0%) 7/20 (35.0%) 3.337 0.794/
15.458
0.113
Diagnosis UC 17/24 (70.8%) 5/7 (71.4%) 0.972 0.076/
7.954
1.000















5/24 (20.8%) 1/7 (14.3%) 1.558 0.13/
86.917
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6/24 (25.0%) 3/7 (42.9%) 0.457 0.057/
4.032
0.384
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remission; endoscopically no signs of inflammation were seen. No side effects occurred. This is
to our knowledge the first report of an IBD patient with infliximab treatment after heart trans-
plantation. Overall, outcome of anti-TNF treatment was good in our cohort, although the
number of patients is small. None of the four anti-TNF treated patients developed infectious
complications; in one UC patient infliximab treatment was stopped prophylactically because of
recurrent episodes of cholangitis most likely caused by stenosis of the biliary-enteric anastomo-
sis. Despite the limited data on anti-TNF therapy, anti-TNF treatment seems effective and safe
in IBD patients post-SOT and refractory to conventional treatment [36–40]. Only one UC
patient needed surgery after SOT with proctocolectomy and ileal pouch-anal anastomosis for
treatment-refractory UC. Tacrolimus-based reject therapy after solid organ transplantation
had a favourable outcome in patients with IBD. The risk for colorectal cancer was low in our
IBD cohort, only one UC patient (3%) was diagnosed with colorectal cancer before SOT and
none of the IBD patients were diagnosed with colorectal cancer after SOT. However, given that
the majority of patients were PSC-IBD patients with a high risk for developing colorectal can-
cer, annual screening colonoscopies were performed in most patients, likely contributing to the
low number of colorectal cancers.
Our study represents one of the largest single-center experiences on SOT outcomes in IBD
patients. A major limitation of our study was the limited number of patients included in the
Table 3. Given is an overview of publications on IBD patients who received anti-TNF therapy after
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A total of 21 IBD patients received anti-TNF therapy after SOT, including 17 patients who received IFX and
4 IBD patients who received ADA treatment after organ transplantation (n/a, not applicable; IFX, infliximab;
ADA, adalimumab).
doi:10.1371/journal.pone.0135807.t003
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analysis; e.g., the subgroup of anti-TNF-treated patients included only four patients. However,
considering that the total number of all anti-TNF-treated IBD-SOT patients in the medical lit-
erature is only n = 21, this study adds important information to our knowledge of how to treat
IBD patients after SOT.
In conclusion, due to the stronger association of PSC-associated liver cirrhosis with UC
(compared to CD), SOT is significantly more often required in UC (4.74% of our patients)
than in CD (0.84% of our patients; p = 2.69 x 10−6, UC vs. CD). The overall outcome of SOT in
our IBD cohort was favourable with a survival rate of 84%. Anti-TNF treatment was effective
and safe in all IBD patients who underwent SOT. This suggests good safety aspects of anti-
TNF-treatment in IBD after SOT, although larger, multi-center cohort analyses are needed to
confirm these findings.
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